Bivalirudin

  • TRADE NAME: Angiomax (The Medicines Company)
  • INDICATIONS: Angioplasty adjunct
  • CLASS: Thrombin inhibitor
  • HALF-LIFE: 25 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Anisindione, Dicumarol, Heparin, Reteplase, Streptokinase, Tenecteplase, Urokinase, Warfarin

PREGNANCY CATEGORY: B

Our database has 11 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RENAL.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of bivalirudin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top